Senior Therapeutic Area Specialist, Neuroscience - Cobenfy – Virginia Beach, VA at Bristol-Myers Squibb

United States

Bristol-Myers Squibb Logo
Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

  • Field-based role requiring 100% time spent with external customers in a defined territory or region
  • High level of scientific expertise in assigned products and therapeutic areas (Neuroscience - Cobenfy)
  • Ability to engage HCPs with differentiated Customer Experience (Cx) through deeper scientific dialogue consistent with label
  • Strong professional credibility with regional thought leaders (RTLs), community-based physicians/HCPs, private practices, medical groups, office staff, and stakeholders
  • Proficiency in using tools like CE^3 to derive insights, inform call plans, and provide feedback for improvement
  • Capability to prepare and implement comprehensive territory and account plans

Responsibilities

  • Promotes approved indications of BMS products to meet or exceed assigned sales targets in a compliant manner
  • Creates demand for BMS medicines by articulating clinical and scientific rationale for use in appropriate patients
  • Engages with and continuously maintains/grows scientific expertise in all assigned products and therapeutic areas
  • Prepares and successfully implements comprehensive territory and account plans
  • Proactively uses available tools such as CE^3 to derive insights and dynamically inform call plans; provides feedback to leadership
  • Demonstrates scientific expertise and passion using approved resources to present balanced information to HCPs, ensuring medical accuracy
  • Conducts in-office presentations (e.g., lunch and learns) and discussions
  • Builds and maintains strong professional relationships with RTLs, community HCPs, and stakeholders as primary point of contact
  • Liaises with other BMS functions to deliver higher Customer Experience by meeting HCP needs timely and scientifically
  • Prioritizes safe and appropriate use of BMS products while focusing on business results, performance objectives, and BMS values

Skills

Therapeutic Area Expertise
Neuroscience
HCP Engagement
Pharmaceutical Sales
Customer Engagement
Demand Generation
BioPharma

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters
1887Year Founded
$33,706.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Benefits

Flexible Work Hours
Hybrid Work Options
Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.
BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.
Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.
The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.
BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.
The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.
BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI